Torrent Pharmaceuticals Limited has registered a standalone net profit of ₹220 crore for the quarter ended March 2018 as against ₹114 crore in the corresponding quarter a year ago, showing a growth of nearly 93 per cent on year-on-year basis.

The company's total revenues for the quarter stood at ₹1,385 crore as against ₹1,082 crore in the same quarter a year ago. For the financial year 2017-18, the standalone net profit stood at ₹482 crore as against ₹854 crore in the previous year, down by 43 per cent. Total standalone revenues for the fiscal stood at ₹4,580 crore as against ₹4,892 crore last year.

On a consolidated basis, the company's net profit for the quarter stood at ₹228 crore as against ₹206 crore in the same quarter a year ago, showing a growth of about 11 per cent on a year-on-year basis. Total revenues for the quarter stood at ₹1,764 crore, up from ₹1,538 crore reported in the corresponding quarter a year ago.

Consolidated net profit for the fiscal 2017-18 stood at ₹678 crore as against ₹934 crore, down by about 27 per cent. The profits are "adjusted for one-off expenses, de-growth was 23 per cent. The tax expense for the year was higher due to deferred tax liability on acquisition related amortisation, impact of tax rate change in US and tax impact of consolidation adjustments of inventory in overseas territories," the company informed.

Total consolidated revenue for the fiscal 2017-18 stood at ₹6,301 crore as against ₹6,080 crore last year.

EBITDA for fiscal 2017-18 was at ₹1,641 crore up by 3 per cent from ₹1,596 crore during 2016-17.

"The company has distributed an interim dividend of ₹9 per equity share of face value of ₹5 during the year. The management and board have recommended a final dividend of ₹5 per share," it informed.

On Thursday, Torrent Pharma shares were trading 1.09 per cent higher at ₹1348.45 on the BSE at about 9.50 am .

Related Topics